Phase II Trial of Busulfan-Based Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed By Reduced Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma

Yi-Bin Chen, Shuli Li, Candice Del Rio, Jessica Driscoll, Hossein Sadrzadeh, Jeremy S. Abramson, Philippe Armand, Jeffrey Barnes, Corey S. Cutler, David C. Fisher, Vincent T. Ho, Ephraim Hochberg (+5 others)
2014 Biology of Blood and Marrow Transplantation  
comorbidity index (HCT-CI) scores > 2 (72% vs 37%, p ¼ 0.009), and pre-NMAT platelets < 25k/uL (33% vs 8%, p ¼ 0.01). In an unadjusted comparison, OS and PFS favored the RIT pts, but the differences were not statistically significant (hazard ratio [HR] for OS ¼ 0.60, 95% confidence interval [CI]: 0.3-1.4, p ¼ 0.24; HR for PFS ¼ 0.75, 95% CI: 0.4-1.5, p ¼ 0.41). However, after adjusting for significant differences between these groups, outcomes for the RIT-treated group were significantly better
more » ... (HR for OS ¼ 0.30; 95% CI: 0.1-0.8, p ¼ 0.007; HR for PFS ¼ 0.42, 95% CI: 0.2-0.9, p ¼ 0.02). With a median follow-up of 81 months in surviving patients, the 3-year adjusted estimates for the RIT and control groups were: OS 87% and 59%, PFS 71% and 44%, respectively (Figures 1 and 2) . Conclusions: These data suggest that the addition of 90 Yibritumomab tiuxetan prior to NMAT may result in improved OS and PFS for patients with persistent iB-NHL. These results set the stage for a prospective randomized comparison of these strategies in this setting.
doi:10.1016/j.bbmt.2013.12.088 fatcat:52wiie7nmzbkdh462hrcsd6nze